Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Glutamic acid decarboxylase (GAD) is an enzyme whose function in the body is to decarboxylate glutamate to GABA. GAD65 antibodies (GAD65Ab) have been associated with type-1 diabetes (80% of new-onset patients) and various neurological conditions, mainly stiff-person syndrome (SPS/PERM), cerebellar ataxia (CA), limbic encephalitis (LE) and temporal lobe epilepsy. These syndromes all seem to result from a reduced transmission of GABA. These neurological conditions are rare and can cause symptoms like confusion, memory loss, muscle stiffness, muscle spasms, behavioural disorders, and pharmacoresistant epilepsy. When finding high levels of GAD65-Ab in the serum, a cerebrospinal fluid (CSF) sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• neurological symptoms with GAD antibody

• GAD antibody in sera and/or CSF

• patient with cerebellar ataxia

Locations
Other Locations
France
Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est
RECRUITING
Bron
Contact Information
Primary
Jérôme Honnorat, professor
jerome.honnorat@chu-lyon.fr
+33 4 72 35 78 06
Backup
Marine Villard, doctor
marine.villard@chu-lyon.fr
+33 4 27 85 54 60
Time Frame
Start Date: 2023-10-01
Estimated Completion Date: 2024-06-30
Participants
Target number of participants: 100
Treatments
Anti-GAD encephalitis
This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov